Form 8-K - Current report:
SEC Accession No. 0001628280-21-016822
Filing Date
2021-08-12
Accepted
2021-08-12 16:18:49
Documents
15
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K blcm-20210812.htm   iXBRL 8-K 35572
2 EX-99.1 exh9912021q2earningsrelease.htm EX-99.1 101495
7 bellicumpressrel_image1a01a.gif GRAPHIC 21803
  Complete submission text file 0001628280-21-016822.txt   339241

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT blcm-20210812.xsd EX-101.SCH 2156
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT blcm-20210812_def.xml EX-101.DEF 14380
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT blcm-20210812_lab.xml EX-101.LAB 27854
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT blcm-20210812_pre.xml EX-101.PRE 14917
8 EXTRACTED XBRL INSTANCE DOCUMENT blcm-20210812_htm.xml XML 10719
Mailing Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098
Business Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098 (832) 384-1100
BELLICUM PHARMACEUTICALS, INC (Filer) CIK: 0001358403 (see all company filings)

EIN.: 201450200 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36783 | Film No.: 211167838
SIC: 2834 Pharmaceutical Preparations